Department of Neurological Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA.
Neurosurgery. 2011 May;68(5):1342-53; discussion 1353. doi: 10.1227/NEU.0b013e31820c0a68.
The management of cerebral arteriovenous malformation (AVM) is challenging, and invasive therapies place vital intracranial structures at risk of injury. The development of noninvasive, pharmacologic approaches relies on identifying factors that mediate key angiogenic processes. Previous studies indicate that endothelial cells (ECs) derived from cerebral AVM (AVM-ECs) are distinct from control brain ECs with regard to important angiogenic characteristics.
To determine whether thrombospondin-1 (TSP-1), a potent angiostatic factor, regulates critical angiogenic features of AVM-ECs and to identify factors that modulate TSP-1 production in AVM-ECs.
EC proliferation, migration, and tubule formation were evaluated with bromodeoxyuridine incorporation, Boyden chamber, and Matrigel studies, respectively. TSP-1 and inhibitor of DNA binding/differentiation 1 (Id1) mRNA levels were quantified with microarray and quantitative real-time polymerase chain reaction analyses. TSP-1 protein expression was measured using Western blotting, immunohistochemical, and enzyme-linked immunosorbent assay techniques. The mechanistic link between Id1 and TSP-1 was established through small interfering RNA-mediated knockdown of Id1 in AVM-ECs followed by Western blot and enzyme-linked immunosorbent assay experiments assessing TSP-1 production.
AVM-ECs proliferate faster, migrate more quickly, and form disorganized tubules compared with brain ECs. TSP-1 is significantly down-regulated in AVM-ECs. The addition of TSP-1 to AVM-EC cultures normalizes the rate of proliferation and migration and the efficiency of tubule formation, whereas brain ECs are unaffected. Id1 negatively regulates TSP-1 expression in AVM-ECs.
These data highlight a novel role for TSP-1 in the pathobiology of AVM angiogenesis and provide a context for its use in the clinical management of brain AVMs.
脑动静脉畸形(AVM)的治疗颇具挑战性,侵袭性治疗会使重要的颅内结构有受伤的风险。非侵入性、药物治疗方法的发展依赖于识别调节关键血管生成过程的因素。先前的研究表明,源自脑 AVM 的内皮细胞(AVM-EC)在重要的血管生成特征方面与对照脑内皮细胞不同。
确定血小板反应蛋白-1(TSP-1),一种有效的血管生成抑制剂,是否调节 AVM-EC 的关键血管生成特征,并确定调节 AVM-EC 中 TSP-1 产生的因素。
通过溴脱氧尿苷掺入、Boyden 室和 Matrigel 研究分别评估 EC 增殖、迁移和小管形成。通过微阵列和实时定量聚合酶链反应分析定量 TSP-1 和 DNA 结合/分化抑制因子 1(Id1)mRNA 水平。使用 Western 印迹、免疫组织化学和酶联免疫吸附试验技术测量 TSP-1 蛋白表达。通过 AVM-EC 中的 Id1 小干扰 RNA 介导的敲低建立 Id1 与 TSP-1 之间的机制联系,然后通过 Western blot 和酶联免疫吸附试验实验评估 TSP-1 产生。
与脑 EC 相比,AVM-EC 增殖更快、迁移更快且形成组织紊乱的小管。TSP-1 在 AVM-EC 中显著下调。将 TSP-1 添加到 AVM-EC 培养物中可使增殖和迁移速度以及小管形成效率正常化,而对脑 EC 没有影响。Id1 负调节 AVM-EC 中的 TSP-1 表达。
这些数据突出了 TSP-1 在 AVM 血管生成病理生物学中的新作用,并为其在脑 AVM 的临床管理中的应用提供了依据。